Decoy Therapeutics Inc. (DCOY) - Total Assets
Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) holds total assets worth $9.00 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Decoy Therapeutics Inc. - Total Assets Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of Decoy Therapeutics Inc. for the company's overall valuation and market capitalisation.
Decoy Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Decoy Therapeutics Inc.'s total assets of $9.00 Million consist of 99.4% current assets and 0.7% non-current assets. Review debt load of Decoy Therapeutics Inc. to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Decoy Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DCOY stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Decoy Therapeutics Inc.'s current assets represent 99.4% of total assets in 2025, an increase from 96.1% in 2014.
- Cash Position: Cash and equivalents constituted 96.9% of total assets in 2025, up from 95.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Decoy Therapeutics Inc. Competitors by Total Assets
Key competitors of Decoy Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Decoy Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.83 | 0.92 | 21.82 |
| Quick Ratio | 1.83 | 0.92 | 21.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.89 Million | $-122.37K | $33.57 Million |
Decoy Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Decoy Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.41 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 265.8% |
| Total Assets | $11.06 Million |
| Market Capitalization | $1.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Decoy Therapeutics Inc.'s assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Decoy Therapeutics Inc.'s assets grew by 265.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual total assets of Decoy Therapeutics Inc. from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $11.06 Million | +265.76% |
| 2024-12-31 | $3.02 Million | -54.10% |
| 2023-12-31 | $6.59 Million | -55.04% |
| 2022-12-31 | $14.65 Million | -64.12% |
| 2021-12-31 | $40.83 Million | +63.78% |
| 2020-12-31 | $24.93 Million | +79.44% |
| 2019-12-31 | $13.89 Million | +33.73% |
| 2018-12-31 | $10.39 Million | -70.31% |
| 2017-12-31 | $34.99 Million | -44.64% |
| 2016-12-31 | $63.21 Million | -33.51% |
| 2015-12-31 | $95.07 Million | +166.96% |
| 2014-12-31 | $35.61 Million | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more